Phenotypes associated with this allele
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tlr7tm1Flv mutation
(1 available);
any
Tlr7 mutation
(21 available)
|
|
|
immune system
|
• in the serum and as glomerular deposition
|
|
• in the serum and as glomerular deposition
|
hematopoietic system
|
• in the serum and as glomerular deposition
|
|
• in the serum and as glomerular deposition
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tlr7tm1Flv mutation
(1 available);
any
Tlr7 mutation
(21 available)
|
|
|
immune system
|
• while IFNalpha secretion in response to infection with vesicular stomatitis virus (a ssRNA virus) was similar to controls, serum levels of IFNalpha were reduced after infection relative to controls
|
homeostasis/metabolism
mortality/aging
|
• survival is prolonged compared to mutant mice wild-type for Tlr7
|
immune system
|
• less severe at 5 months of age compared to mutant mice wild-type for Tlr7
|
|
• activation of splenocytes is reduced compared to mutant mice wild-type for Tlr7
|
|
• autoantibodies show a homogeneous nuclear pattern
|
|
• develop a lupus like syndrome at a later age and in lower numbers compared to mutant mice wild-type for Tlr7
|
|
• increase in anti-RNA IgG levels in the serum at 4 - 6 months of age is less severe than in mutant mice wild-type for Tlr7 and is similar to mice homozygous for Fcgr2btm1Ttk alone
|
renal/urinary system
|
• kidney disease is less severe at 5 months of age compared to mutant mice wild-type for Tlr7
|
hematopoietic system
|
• less severe at 5 months of age compared to mutant mice wild-type for Tlr7
|
|
• activation of splenocytes is reduced compared to mutant mice wild-type for Tlr7
|
growth/size/body
|
• less severe at 5 months of age compared to mutant mice wild-type for Tlr7
|
hematopoietic system
N |
• spleen marginal zone B cell numbers are similar to wild-type controls
• splenocyte proliferation in response to imiquimod is similar to controls
|
immune system
|
• decrease in accumulation of double-negative T cells in the spleen compared to Faslpr homozygotes
|
|
• decrease in proportion of CD4+ T cells expressing CD44, both in the lymph node and spleen compared to Faslpr homozygotes
|
|
• spleen weight is decreased compared to Faslpr homozygotes
|
|
• general B cell activation is inhibited compared to Faslpr homozygotes, as indicated by decreased CD44 expression in splenic B cells
|
|
• serum IgG2a levels are decreased compared to Faslpr homozygotes
|
|
• serum IgG3 levels are decreased compared to Faslpr homozygotes
|
|
• lymph node weight is decreased compared to Faslpr homozygotes
|
|
• plasmacytoid DCs exhibit a more immature phenotype compared to Faslpr homozygotes, with decreased expression of MHC class II
|
|
• renal disease is significantly decreased compared to Faslpr homozygotes, with mice showing decreased glomerular protein deposition and preserved glomerular structure
• although skin disease is evident in mutants, it occurs with a very low frequency and very little is seen at 16 weeks of age
|
|
• mutants exhibit impaired generation of antibodies to RNA complexes and generation of high-titer Smith antibodies is blocked
|
|
• DNA autoantibodies are seen in mutants
|
hematopoietic system
|
• decrease in accumulation of double-negative T cells in the spleen compared to Faslpr homozygotes
|
|
• decrease in proportion of CD4+ T cells expressing CD44, both in the lymph node and spleen compared to Faslpr homozygotes
|
|
• spleen weight is decreased compared to Faslpr homozygotes
|
|
• general B cell activation is inhibited compared to Faslpr homozygotes, as indicated by decreased CD44 expression in splenic B cells
|
|
• serum IgG2a levels are decreased compared to Faslpr homozygotes
|
|
• serum IgG3 levels are decreased compared to Faslpr homozygotes
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tlr7tm1Flv mutation
(1 available);
any
Tlr7 mutation
(21 available)
|
|
|
immune system
|
• absence of the splenocyte proliferation response to imiquimod
|
hematopoietic system
|
• absence of the splenocyte proliferation response to imiquimod
|
cellular
|
• absence of the splenocyte proliferation response to imiquimod
|